Get the Latest News on Our Pharmaceutical Company

qtq80-mRBbDE

AiViva Biopharma Receives FDA Clearance to Administer AIV001 in Facial Skin by Intradermal Injection for Nonmelanoma Skin Cancer

December 9, 2024

qtq80-MbEtVo

AiViva Biopharma Completes Enrollment in a Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema

August 23, 2024

qtq80-4xx4lt

AiViva Biopharma Completes Phase 1/2 Clinical Trial of AIV001 Administration in Patients with Nonmelanoma Skin Cancer

December 11, 2023

qtq80-EkxBL0

AiViva BioPharma Appoints Les Kaplan, PhD, to the Board of Directors

September 18, 2023

qtq80-RU8WIl

AiViva BioPharma Appoints Jung-Chin (Rongjin) Lin, to the Board of Directors

August 30, 2023

Latest News - CMO Announcement Page

AiViva BioPharma Initiates Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema

May 22, 2023

recent news

AiViva BioPharma Announces New Patent Received

August 17, 2022

qtq80-BtcCPt

AiViva BioPharma is recognized by Life Sciences Review as Top 20 Clinical-Stage Biopharmaceutical Company for 2022

May 24, 2022

DNA strand

AiViva BioPharma Initiates Phase 1/2 Clinical Trial of AIV001 for Nonmelanoma Skin Cancer

October 2, 2020

Molecules

AiViva BioPharma Announces Positive Data from Phase 1/2a Clinical Trial of AIV001 for Dermal Scarring and Wound Healing

June 25, 2020

Get AiViva Investor Brief